{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038444","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.593985+00:00","generated_at":"2026-06-04T08:21:11.856967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash","bullets":["FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.","Net loss for FY2023 $16.0M ($0.60 per share) vs $23.7M ($0.90) in 2022; Q4 net loss $2.7M ($0.10).","Cash and equivalents $13.2M at Dec 31, 2023; pro forma cash >$55M after receiving ~$43M upfront from Norgine licensing deal.","Entered exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, NZ; potential up to ~$230M milestones plus tiered royalties.","FDA issued public reminder that PEDMARK is not substitutable with other sodium thiosulfate products."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038444","json":"https://secwatch.observer/filing/0001104659-24-038444.json","markdown":"https://secwatch.observer/filing/0001104659-24-038444.md","text":"https://secwatch.observer/filing/0001104659-24-038444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/tm249737d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:21:11.856967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3845b99f81297f73ddb266f8fe4d45f718ebc46b","claim":"FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.","evidence_excerpt":"Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924038444/0001104659-24-038444-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year and fourth quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}